Indeed, for patients with unresectable stage III NSCLC, the PACIFIC trial has revealed a profound clinical benefit treatment with the anti-PD-L1 monoclonal antibody durvalumab after chemoradiotherapy with remarkably low toxicities [8, 9]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.